/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
EUR/USD
-1.07%
Natural Gas
-2.67%
Gold
-2.58%
BTC
-0.89%
ETH
+0.43%
SPX
-1.03%
VIX
-2.14%
Economic Calendar
EUR/USD
-1.07%
Natural Gas
-2.67%
Gold
-2.58%
BTC
-0.89%
ETH
+0.43%
SPX
-1.03%
VIX
-2.14%
Economic Calendar
BTC
-0.89%
ETH
+0.43%
XRP
-0.84%
ADA
-0.59%
SOL
-0.19%
Review
Review
Review
Tesla’s Elon Musk found not liable in trial over 2018 ‘funding secured’ tweets
9 minutes ago
Russia’s war on Ukraine latest: Zelenskiy vows to defend ‘fortress’ Bakhmut
39 minutes ago
China says political trust with Russia has deepened after envoy’s visit
about 2 hours ago
U.S. judge denies FTC request to stop Meta from acquiring VR firm Within
about 2 hours ago
Japan PM Kishida rebukes aide over same-sex couple outburst
about 2 hours ago
South Sudan’s late liberation hero Garang in focus during pope’s visit
about 2 hours ago
BTC Fear & Greed Index Stays Greedy Despite a Bearish BTC
about 2 hours ago
If You Did Not Hear This Coming, You Had Better Get Your Ears Checked
about 6 hours ago
Deepening Bearish Sentiment in Natural Gas Takes it to New Lows
about 10 hours ago
S&P 500’s Rally to $4300+ Is Still on Track
about 10 hours ago
NASDAQ, S&P 500, Dow Jones Analysis – Stocks Retreat As Treasury Yields Rally
about 10 hours ago
S&P 500 Weekly Price Forecast – Stock Markets Continue to Look Higher
about 11 hours ago
Quick Links
:
Forecasts
Economic Calendar
Crypto
Commodities
FXTM Academy
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
JAZZ
profile
Jazz Pharmaceuticals plc
Follow
JAZZ
(
Nasdaq - US
)
Closed
155.61
-0.79 (-0.51%)
in
:
usd
•
As of: Feb 03, 2023 15:59
UTC -5
Open
157.65
High
158.27
Low
155.30
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Jazz Pharmaceuticals plc
CEO
Bruce C. Cozadd
Headquarters
fifth floor, waterloo exchange, waterloo road
dublin, l2 d04, ireland
Auditor
KPMG
Employees
3,200
Share Holders
907
Website
www.jazzpharma.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
Jazz Pharmaceuticals plc
Statistics
Valuation Measures
Market Capitalization
2
9.80B
Enterprise Value
14.69B
Enterprise Value/EBITDA
(ttm)
16.38
Price to Earnings Ratio
(ttm)
10.56
Price to Book
(mrq)
3.59
Price to Sales
(ttm)
2.77
Price to Cash
(ytd)
6.87
Profitability
Gross Margin
(ttm)
85.78%
Operating Margin
(ttm)
28.96%
Profit Margin
(ttm)
-0.53%
Return on Equity
(ttm)
30.71%
Return on Invested Capital
(ttm)
-0.19%
Return on Assets
(ttm)
9.10%
Income Statement
Revenue
(ttm)
3.58B
Revenue Per Share
(ttm)
56.92
Gross Profit
(ttm)
3.07B
EBITDA
(ttm)
3
896.60M
Net Income Avi to Common
(ttm)
-18.69M
Diluted EPS
(ttm)
-0.30
Share Statistics
Beta (5Y Monthly)
0.71
52-Week Change
10.41%
S&P500 52-Week Change
-8.09%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
62.97M
Dividend Yield
0.00%
Float
4
60.20M
%
Held by Insiders
4.40%
%
Held by Institutions
89.79%
Balance Sheet
Total Cash
(mrq)
899.36M
Total Cash Per Share
(mrq)
14.28
Total Debt
(mrq)
5.73B
Total Debt/Equity
(mrq)
208.61%
Current Ratio
(mrq)
3.16%
Quick Ratio
(mrq)
2.27%
Book Value Per Share
(mrq)
43.65
Cash Flow
Operating Cash Flow Per Share
(ytd)
14.81
Free Cash Flow
(ytd)
910.34M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker